Ferrari will continue to invest in petrol, hybrid and EV powetrains, CEO says
MILAN, April 16 (Reuters) - Luxury sportscar maker Ferrari (RACE.MI), opens new tab will continue to develop petrol, hybrid and full-electric vehicles, its Chief Executive Bendetto Vigna said on Wednesday during the company's annual shareholders' meeting.
"Indeed ... we continue to invest in all three powertrains - internal combustion engine, hybrid, and full electric - to offer our clients maximum freedom of choice," Vigna said.
Stay up to date with the latest news, trends and innovations that are driving the global automotive industry with the Reuters Auto File newsletter. Sign up here.
Known globally for its roaring petrol engines, Ferrari started selling hybrid models in 2019 and will unveil its fist fully-electric (EV) model in October.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
9 minutes ago
- Reuters
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial
June 9 (Reuters) - Shares of weight-loss drug developer Metsera (MTSR.O), opens new tab gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a monthly dosing regime. The drug developer, which went public in January, is one of the many that are eyeing the lucrative market of weight-loss drugs that have been dominated by GLP-1 drugs from Novo Nordisk ( opens new tab and Eli Lilly (LLY.N), opens new tab. The drug, MET-233i, helped patients lose 8.4% of their weight, when adjusted for placebo, at 36 weeks. The drug belongs to a class of medicines which mimic the pancreatic hormone amylin that is co-secreted with insulin. It is being developed as a standalone treatment, and in combination with the company's other GLP-1 drug MET-097i. The two hormones combined suppress hunger, help control patients' blood glucose. Metsera's shares, which touched $35.19 in early trading, were up 5% at midday. The first wave of obesity drugs was based mainly on the gut hormone GLP-1, but drugmakers are looking for medicines that target other hormones or help preserve muscle while losing fat for their next generation of drugs. Data from Novo Nordisk's experimental drug CagriSema, which was touted to be the successor of its blockbuster obesity drug Wegovy, has so far fallen below investor expectations. Data from Metsera's 80-patient study showed that its drug has a half life of about 19 days, supporting once-a-month dosing. This compares to the five to seven days for Lilly's Zepbound and Novo's Wegovy that are taken weekly, said Evercore ISI analyst Umer Raffat. The so-called half life of a drug refers to the time it takes for the initial dose of the medicine to decrease by half in a patient's body. It helps determine how frequently a drug should be taken to achieve benefits. Drugmaker AstraZeneca (AZN.L), opens new tab is also testing an amylin-based obesity drug in early trials.
Daily Mail
an hour ago
- Daily Mail
Lewis Hamilton reaching 'critical' point of underwhelming debut season with Ferrari - as F1 expert warns of 'growing concerns' in the Scuderia
Lewis Hamilton 's early season struggles with new team Ferrari has resulted in the upcoming Canadian Grand Prix becoming a 'critical' point in his campaign, believes Sky Sports' Karun Chandhok. The seven-time world champion is still waiting for his first podium since joining the Scuderia from Mercedes, with his sixth-place finish at the Spanish GP providing the latest example of his travails. According to former F1 driver Chandhok, there could now be 'concerns creeping in' at the constructor after a race in which Hamilton was told to let his teammate Charles Leclerc pass him after he was unable to keep pace with the the two McLarens and Max Verstappen. Chandhok shared the view that Hamilton is struggling for rhythm and consistency after being 'comfortably' beaten by Leclerc, who finished third, notching a trio of podium finishes. 'It's starting to get a bit critical,' he said on the The F1 Show. 'We're coming into the second third of the season now, and he's not finding the rhythm. He's not finding consistency where week in, week out, he's in a happy place of the car. 'In Imola, he was woeful in qualifying, then suddenly the car's brilliant in the race. In Monaco, he wasn't quite there. He was a chunk behind Charles throughout. There's got to be a degree of concern creeping in. When you look at Spain, the fact that Charles overtook him and drove away from him quite comfortably, even before we go into the different tyres and stuff later on. 'If I was on the Lewis side of the garage, I would be concerned. We are nearly at halfway through the year now, we need to start understanding whether this a fundamental issue, that we need to change the direction of the set-up of the car. 'I'm not disputing that he's still got the ability. He clearly does. He's able to win races, we saw that in China, but they need to find a sweet spot for him, where every weekend he knows what he's got, and they haven't got that. He's still having too many good days and bad days. The fluctuations are too much.' A dejected Hamilton made a brutal admission about his performance after his lacklustre showing in Spain last week. After reappearing for his post-race media duties, the visibly frustrated 40-year-old couldn't help but snap while speaking to Sky Sports. Pressed on his comment over team radio that there was 'something wrong' with his car, and for his immediate reaction to the race, Hamilton replied: 'Not particularly, it was not a great day. The strategy was good, the team did a great job. Just, that's it.' Sky interviewer Rachel Brookes then told Hamilton: 'I hate seeing you in this mood.' But Hamilton quickly fired back, replying: 'Well what do you want me to say? I had a really bad day and I've got nothing to say. 'It was a difficult day, I've got nothing else to add to it. There's no point explaining it. It's not your fault, I've just not got anything to say.' Brookes admitted she hopes Ferrari will be able to find a fix for his woes, but Hamilton said: 'I'm sure they won't, the answer is probably just me.' Hamilton trails Leclerc by 23 points in the drivers' championship and, damningly, has finished six of his first nine Ferrari races outside of the top five. There have been criticisms of Hamilton's car this season, with team principal Fred Vasseur claiming there was an issue with the vehicle towards the end of the Spanish GP. The Ferrari team boss has since backed the veteran and insisted he needs only adjust 'the details' to challenge for podiums this term. 'Hamilton is only missing the details,' said Vasseur. 'We are talking about hundredths, which in this balanced Formula 1 can make the difference between a first and a third row - between a good weekend and a less good one. 'ut they remain details - understanding the car, setup, communication. It's normal when you change teams. Frustration? It's understandable.'
Reuters
an hour ago
- Reuters
US wholesale inventories in April revised higher
WASHINGTON, June 9 (Reuters) - U.S. wholesale inventories increased in April amid stockpiling of prescription medication in anticipation of tariffs from the Trump administration. Stocks at wholesalers rose 0.2% instead of being unchanged, as estimated last month, the Commerce Department's Census Bureau said on Monday. Economists polled by Reuters had expected last month's estimate would be unrevised. Inventories, a key part of gross domestic product, climbed 0.3% in March. They advanced 2.3% on a year-over-year basis in April. Wholesale stocks of prescription medication surged 1.3% in April. There were also increases in apparel, motor vehicle, groceries and professional equipment inventories. President Donald Trump has said he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm to patients. Apart from drugmakers, businesses front-loaded imports in the first quarter, seeking to avoid Trump's sweeping duties on foreign goods, resulting in a large trade deficit that subtracted a record 4.90 percentage points from GDP. The front-running faded in April, leading to a record decline in imports and the overall trade deficit. While the contraction in the deficit at face value suggests trade could significantly add to gross domestic product in the second quarter, economists say some of the boost could be offset by low inventories. Inventory accumulation increased at a rate of $163.0 billion in the first quarter. The economy contracted at a 0.2% annualized rate in the January-March period, the first GDP decline in three years. It grew at a 2.4% pace in the fourth quarter. Sales at wholesalers edged up 0.1% in April after jumping 0.8% in March. At April's sales pace it would take wholesalers 1.30 months to clear shelves, unchanged from March.
